Unigene, Nordic sign equity transfer, exclusive license agreement for metabolic peptide analogs
As per the terms of the equity transfer and exclusive license agreement, Nordic has agreed to pay $1,000,000 for Unigene’s ownership interest in the JDV. As part of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.